Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for global professionals · Wednesday, December 1, 2021 · 557,348,563 Articles · 3+ Million Readers

Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030 by Roots Analysis

Vaccine Contract

Vaccine Contract

Vaccine Contract Manufacturing

Vaccine Contract Manufacturing

Vaccine Contract Manufacturing (CMO)

Vaccine Contract Manufacturing (CMO)

Roots Analysis logo

Roots Analysis logo

Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030 by Roots Analysis

LONDON, ENGLAND, UNITED KINGDOM, October 19, 2021 / -- Roots Analysis has announced the addition of “Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030” report to its list of offerings.

Several of the larger CMOs have developed the required capabilities and expertise to offer end-to-end services, ranging from vaccine development (which includes preliminary R&D, preclinical studies and clinical trials) to regulatory filings, and commercial scale production.

To order this 350+ page report, which features 135+ figures and 160+ tables, please visit

The financial opportunity within the vaccine contract manufacturing market has been analyzed across the following segments:
 Scale of Operation
 Preclinical
 Clinical
 Commercial
 Type of Expression System
 Mammalian
 Microbial
 Others
 Outsourced Business Operations
 API Manufacturing
 Fill / Finish
 Others
 Company Size
 Small
 Mid-sized
 Large / Very Large
 Key geographical regions
 North America
 Europe
 Asia-Pacific
 Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, the current vaccine manufacturing revenues are primarily driven by outsourcing of various processes involved in the development of preventive vaccines. The report includes detailed transcripts of discussions held with the following experts:
 Menzo Havenga (President and Chief Executive Officer, Batavia Biosciences) and Claire Otjes (Marketing Manager, Batavia Biosciences)
 Dietmar Katinger (Chief Executive Officer, Polymun Scientific)
 David C Cunningham (Director Corporate Development, Goodwin Biotechnology)
 Ingrid Cromann (Director - Vaccine Development, Statens Serum Institut)
 Kevin Daley (Director Pharmaceuticals, Novasep Synthesis)
 Thilo Kamphausen (Director Business Development, Richter-Helm BioLogics)
 Sebastian Schuck (Head of Business Development, Wacker Biotech)
 Oliver Schub (Senior Business Development Manager, ProBioGen)

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Market Landscape

5. COVID-19 Vaccine Contract Manufacturers

6. Company Competitiveness Analysis

7. Company Profiles: Vaccine Contract Manufacturers based in North America

8. Company Profiles: Vaccine Contract Manufacturers based in Europe

9. Company Profiles: Vaccine Contract Manufacturers based in Emerging

10. Partnerships and Collaborations

11. Recent Expansion

12. Mergers and Acquisitions

13. Capacity Analysis

14. Demand Analysis

15. Market Forecast

16. SWOT Analysis

17. Future Growth Opportunities

18. Executive Insights

19. Concluding Remarks

20. Appendix 1: Tabulated Data

21. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit

For additional details, please visit or email

You may also be interested in the following titles:
1. mRNA Synthesis and Manufacturing Services Market, 2021-2030
2. Biopharmaceutical CROs Market, 2021-2030
3. Cold Chain Logistics Market for Vaccines, 2021 –2030

Ben Johnson
+1 (415) 800 3415

Gaurav Chaudhary
Roots Analysis
+1 415-800-3415
email us here
Visit us on social media:

Powered by EIN Presswire

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release